Robert Stott News Today

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release. Originally given breakthrough therapy designation in 2019, Iqirvo (elafibranor, Ipsen/Genfit), is now indicated as second-line therapy in combination with

The Skoda was being driven by a 75-year-old woman when it came to halt just feet away from staff.

A BRAND new car has ploughed through the window of a shop in a Cheshire town centre.

A YOUNG north Cumbrian farmer caused head-on crash that left two people seriously injured after he “lost concentration.”

CHARLOTTE, N.C. — The CHESS-ALARM score was a better predictor of esophageal varices requiring treatment in patients with cirrhosis vs. other noninvasive criteria, according to data presented at the ACG Annual Scientific Meeting. “During the COVID-19 pandemic, there was a shortage of resources to perform endoscopy procedures, including availability of staff and diversion of resources,

The ACG and the AGA Gastrointestinal Opportunity Fund have made “strategic” financial investments in Oshi Health to quicken the adoption of a whole-person multidisciplinary hybrid care model for digestive health, according to a release.The collaboration between ACG, AGA and Oshi Health will allow for GI practices to offer dietary and behavioral health interventions based on guideline

The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.This approval marks the second rare cholestatic liver disease indication for Bylvay (odevixibat, Ipsen/Albiero Pharmaceuticals), a non-systemic ileal bile acid transport inhibitor originally approved in 2021 for

The FDA has approved Linzess, the first oral therapy for pediatric functional constipation in patients aged 6 to 17 years, according to an agency release. Previously approved for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation, the new drug application for Linzess (linaclotide 72 mcg, AbbVie/Ironwood) was assigned a Prescription Drug User

UnitedHealthcare recently announced that beginning June 1, 2023, commercial plan members will be required to obtain prior authorization for gastroenterology endoscopy services. By far the largest health insurance company in the United States, UnitedHealthcare generates more than $286 billion in total revenue — more than double that of the next closest competition, Anthem —and serves

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.Yuflyma (adalimumab-aaty, Celltrion USA) is a high-concentration (100 mg/mL), citrate-free biosimilar to the world’s top-selling Humira (adalimumab, AbbVie),